Upstream Bio Q3 net loss widens 22% to $41.19 million
UPB•Upstream Bio’s third-quarter 2026 net loss widened 22% year over year to $41.19 million, while collaboration revenue fell 42% to $395,000. The company reported $207.4 million in cash, cash equivalents and short-term investments, expected to fund planned operations through 2027.
1. Quarterly results
Upstream Bio’s third-quarter 2026 net loss widened 22% year over year to $41.19 million, and collaboration revenue fell 42% to $395,000. Cash, cash equivalents and short-term investments totaled $207.4 million at September 30, which the company expects to fund planned operations through 2027. Phase 3 verekitug trials in severe asthma and chronic rhinosinusitis with nasal polyps are planned for the first quarter of 2027.
